Lu Shao-Ta 4

What Happened
Lu Shao‑Ta, a director of YD Bio Ltd (YDES), was granted restricted share units (RSUs) with an aggregate target grant‑date fair value of $60,000 and on March 31, 2026 became entitled to a fixed number of RSUs (2,081). The filing also reports the conversion/exercise of the derivative representing those RSUs into 2,081 ordinary shares. The reported acquisition price was $0, indicating the shares were received as an award/settlement rather than an open‑market purchase.

Key Details

• Transaction date: March 31, 2026 (reported on Form 4 filed April 2, 2026 — timely filing).
• Reported transactions/codes: A = Award/Grant (2,081 RSUs); M = Exercise/Conversion of derivative (2,081 shares).
• Shares received: 2,081 ordinary shares acquired upon conversion; insider paid $0 for these shares.
• Aggregate target grant‑date fair value for the Granted RSUs: $60,000 (per footnote).
• Vesting: Granted RSUs vest in four equal quarterly installments beginning March 31, 2026; the number per installment is determined by dividing $15,000 by a 7‑day VWAP ending the trading day prior to each vesting date. Footnote indicates the Reporting Person became entitled to a fixed number on the vesting date.
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Form 4 was filed within the normal reporting window (not marked late).

Context
RSUs are a type of equity award that give the holder a contingent right to receive ordinary shares (one RSU = one share when settled). The M code here reflects conversion/settlement of that derivative right into shares; since no cash was paid, this is consistent with a standard RSU settlement rather than an option exercise that required cash. This is an award/settlement (not a sale), so it does not signal insider selling pressure; it represents compensation/equity participation under the company’s equity incentive plan.